EGFR and lung carcinoma: The first generation of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), represented by gefitinib, could significantly prolong the median survival of patients with advanced lung cancer with EGFR-sensitive mutations and greatly improve their quality of life3.